LUGANO, Switzerland • September 4th, 2025 • At Cerbios-Pharma SA, we are fully committed to integrating sustainable practices into every aspect of our operations, recognizing our responsibility towards the environment and the communities we serve. In line with this ongoing commitment, we are proud to publish our latest Sustainability Report, detailing our key efforts in…
LUGANO, Switzerland • May 7th, 2025 • HAS Healthcare Advanced Synthesis SA completes the acquisition of Cerbios-Pharma SA to establish a top-tier global group in the CDMO industry, backed by 65 Equity Partners. Download the Press Release
LUGANO, Switzerland • March 31th, 2025 • Today we are proud to announce that Cerbios-Pharma SA, Switzerland and HAS Advanced Synthesis SA, Switzerland (HAS), are joining their forces. Download the Press Release
LUGANO, Switzerland • February 28th, 2025 • Cerbios-Pharma is proud to announce the opening of a new expansion area at the Lugano site for clinical and commercial manufacturing of Highly Potent Active Pharmaceutical Ingredients (HPAPIs), including cytotoxic linker payloads for antibody-drug conjugates (ADCs). The inauguration was conducted in the presence of Christian Suà, CEO of…
LUGANO, Switzerland • April 8th, 2024 • Cerbios-Pharma SA is proud to announce the completion of a photovoltaic power plant at its Lugano site. This new milestone marks a significant step forward in the Company’s commitment to environmental protection and sustainability, further to last year’s implementation of a new solvent collection and separation process which…
LUGANO, Switzerland • May 10th, 2023 • During our long standing 45 years history in the pharmaceutical industry, as Cerbios-Pharma, we have always invested in expanding our capabilities and in the last years more and more resources were addressed to support our customers with innovative CDMO services for HPAPIs and ADCs. Today, we are pleased…
Indications: for maintenance of normal blood levels of cholesterol and normal metabolism of homocysteine
Regulatory status: Food Supplement (EU & Switzerland)
LUGANO, Switzerland • May 31th, 2022 • Cerbios-Pharma SA announces the opening, at its Lugano site, of an additional R&D laboratory unit equipped with state-of-the-art technologies. This new space will host an area for the development activities related to Highly Potent Molecules and a separate section for the analytical support of CDMO projects. These laboratories, designed…
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
